@bernamadotcom #WHODailyBriefing:-
1) There are 9 vaccines under evaluation ~ Dr. Tedros
2) Working with vaccine manufacturers to allow all countries working with #COVAX to obtain the vaccine at the lowest possible price, as soon as there's a safe and effective vaccine.
1) There are 9 vaccines under evaluation ~ Dr. Tedros
2) Working with vaccine manufacturers to allow all countries working with #COVAX to obtain the vaccine at the lowest possible price, as soon as there's a safe and effective vaccine.
3) Initial supply of the vaccine roll out would be those at the highest risk: Health care workers and the elderly.
4) If we all DO IT ALL (wear facemasks, practise hand hygiene and practise safe distancing) we can break the chain of transmission.
4) If we all DO IT ALL (wear facemasks, practise hand hygiene and practise safe distancing) we can break the chain of transmission.
5) We're learning new things about this virus every day
6) Question about HK reinfection case and implications for herd immunity etc.
Answer: People do develop an immune response. It would be good if sequencing can be done in reinfection cases - in this case 14 nt difference!
6) Question about HK reinfection case and implications for herd immunity etc.
Answer: People do develop an immune response. It would be good if sequencing can be done in reinfection cases - in this case 14 nt difference!
7) Longitudinal studies are being done ~ Dr. Maria Van K. Need to see if this individual developed a neutralising Ab response.
8) Important to convince recipients of vaccine benefits and quality of vaccine, instead of requiring mandatory vaccination.
8) Important to convince recipients of vaccine benefits and quality of vaccine, instead of requiring mandatory vaccination.
9) Criteria for safe & effective vaccine - minimum coverage by vaccine candidate. Look forward to discussing with Russian authorities.
10) Importance of Multi armed: adaptive vaccine trial.
10) Importance of Multi armed: adaptive vaccine trial.
11) Q on MAbs?! Answer: Interest in Mabs that attach to binding site of virus.
12) NIH conducting clinical trials.
13) Difficult but would be very useful in the long run.
14) Cost would be high. Looking at possibility of scale up capacity to make them affordable.
12) NIH conducting clinical trials.
13) Difficult but would be very useful in the long run.
14) Cost would be high. Looking at possibility of scale up capacity to make them affordable.
15) Q on how they would be used? Mabs (if they work) may be useful where vaccines aren't available. Or a combination of both.
@threadreaderapp Unroll
